Nivalis Therapeutics, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.nivalis.com
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)β’ Click on a phase to view related trials
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Nivalis Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02934139
- Locations
- πΊπΈ
DaVita Clinical Research, Lakewood, Colorado, United States
Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Nivalis Therapeutics, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02724527
- Locations
- πΊπΈ
National Jewish Health, Denver, Colorado, United States
πΊπΈJohns Hopkins Hospital, Baltimore, Maryland, United States
πΊπΈBoston Children's Hospital, Boston, Massachusetts, United States
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Nivalis Therapeutics, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT02589236
- Locations
- πΊπΈ
University of Alabama, Birmingham, Alabama, United States
πΊπΈBanner University of Arizona Medical Center, Tucson, Arizona, United States
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Nivalis Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02500667
- Locations
- πΊπΈ
St. Anthony's Medical Plaza 1, Lakewood, Colorado, United States
Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Nivalis Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02275936
- Locations
- πΊπΈ
University of Alabama @ Birmingham, Birmingham, Alabama, United States
πΊπΈStanford University, Palo Alto, California, United States
πΊπΈChildren's CO, Aurora, Colorado, United States
- Prev
- 1
- 2
- 3
- Next